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Background: Treatment-emergent comorbid events (TECs) are common In patients initiating treatment with
pegylated interferon alpha (PEG-IFN-alfa) and ribavirin for chronic hepatitis C virus (HCV) infection. The purpose of
this study was to estimate the incidence and incremental cost of these events.
Methods: In a retrospective cohort analysis of healthcare claims, we studied patients with HCV who were newly
treated with PEG-IFN-alfa/ribavirin between 2006 and 2008. TECs were defined by new medical/pharmacy claims
for predefined conditions in the 12 months after treatment initiation. The net incremental cost of the TECs was
the difference between baseline and follow-up costs for these comorbidities and their treatment, excluding
PEG-IFN-alfa/ribavirin costs.
Results: Of 3,795 newly treated patients, 1,269 (mean age 50.2, 36.2% female) met the selection criteria. New TECs
were common, with 61.6% of patients having ≥1 event. Anemia was identified in 29.2% of patients, fatigue in
16.4%, depression in 11.5%, and neutropenia in 11.0%. The mean incremental cost for the predefined TEC in the
postindex period was $6,377 ($2,782 for medical and $3,595 for pharmacy claims).
Conclusions: In an insured US cohort with chronic HCV infection, TECs with PEG-IFN-alfa/ribavirin were common
and increased costs by approximately $6,000 per treated patient. This estimate may be conservative because it
excludes indirect costs. Costs might increase with new regimens that include a protease inhibitor because
additional TECs may be expected. Better-tolerated therapies that reduce the financial burden on the healthcare
system and improve patient experience are needed.
Keywords: Insurance claims, Retrospective study, Pegylated interferon alpha, RibavirinBackground
Chronic hepatitis C virus (HCV) infection, with a worldwide
prevalence of 2%-3% [1], causes substantial loss of life and
reduces quality of life in those who are infected [2].
Although the screening of blood products has reduced the
incidence of HCV infection in developed countries, there
is a long latency period before the disease becomes
symptomatic and thus large numbers of new cases
will continue to be identified over the coming years.* Correspondence: mbroder@pharllc.com
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unless otherwise stated.Estimates suggest that about half of the 3.1 million US
patients infected with HCV are unaware of their infection
and only a small fraction have been treated [3-5].
Under optimal conditions, treatment of chronic HCV
infection with pegylated interferon alpha (PEG-IFN-alfa)
and ribavirin dual therapy produces sustained virologic
response (SVR) of above 50% in patients with HCV
infection [6,7]. For patients with the most common HCV
genotype (GT) in the US, GT-1, 48 weeks of PEG-IFN-alfa/
ribavirin results in an SVR in 45%-50%, whereas in patients
with GT-2 and GT-3, 24 weeks of PEG-IFN-alfa/ribavirin
results in an SVR in 80%. Nearly all patients who achieve a
SVR are cured of infection [8] and have a reduced risk oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ment with PEG-IFN-alfa/ribavirin causes numerous adverse
events including fatigue, flulike symptoms, gastrointestinal
disturbances, psychological symptoms, and hematologic
abnormalities [10]. These adverse events lead to decreased
adherence, dose reduction, and early discontinuation.
Patients who are able to maintain at least 80% adherence
to their drug regimen have the highest likelihood of
achieving a SVR, but treatment-emergent comorbid events
(TECs) commonly limit adherence [10-12].
In the initial treatment of HCV infection, the addition
of a protease inhibitor (telaprevir or boceprevir) to
PEG-IFN-alfa/ribavirin (triple therapy) significantly
improved SVR [13,14]. However, adverse events were
reported at higher rates among users of triple therapy
than among users of PEG-IFN-alfa/ribavirin [13,14].
Although a small subset of patients receiving triple
therapy who have a rapid response can receive a
shorter course of treatment, the 47%-77% premature
discontinuation rates of PEG-IFN-alfa/ribavirin reported
in clinical care settings [15,16] would likely be similar with
triple therapy.
Premature discontinuation of treatment and nonad-
herence may cause viral resistance and increase costs.
Although combination therapies to treat HCV may cost
between $23,000 and $78,000 per year (depending on
GT, patient weight, and drug selected) [17], treatment
with PEG-IFN-alfa/ribavirin has been shown to be cost
effective when patients are cured [18]. In addition,
nonadherent patients have higher HCV-related medical
(i.e., excluding medication) costs than adherent patients
[19]. However, despite their frequency and effect on
treatment success, little is known about the cost associated
with adverse events due to treatment with PEG-IFN-alfa/
ribavirin itself [20]. The objective of this study was to
estimate the incidence of TECs and the incremental
costs of treating these events in insured patients initiating
PEG-IFN-alfa/ribavirin treatment for chronic HCV
infection. Secondary objectives were to explore, in a
managed care population, the rate of discontinuation of
PEG-IFN-alfa/ribavirin therapy and the temporal pattern
of the costs of these TECs.
Methods
Study design and data source
This study was a retrospective cohort analysis that used
data from the i3 Ingenix LabRx database spanning
the 4-year period from 7/1/05 to 6/30/09. This database
is a Health Insurance Portability and Accountability Act
(HIPAA)-compliant administrative claims database of
8–10 million covered lives, representing all major
regions of the US. The database contains deidentified
adjudicated pharmacy and medical claims submitted for
payment by providers, healthcare facilities, and pharmaciesand includes information on physician visits, medical
procedures, hospitalizations, drugs dispensed, and
tests performed. Healthcare charges are reported (medical,
inpatient, and pharmacy) in this database, but paid claims
and costs are not. Also available are member enrollment
and benefit information as well as limited patient,
provider, and hospital demographic information. Since the
study did not involve direct contact with human subjects,
did not involve an intervention, and did not involve collec-
tion of any identifiable patient information, Institutional
Review Board (IRB) approval was not required.
Study population
The study included treatment-naive patients with
HCV infection who began treatment with PEG-IFN-alfa/
ribavirin during a 2-year period between 7/1/06 and 06/
30/08. PEG-IFN-alfa and ribavirin were identified using
National Drug Codes. The date of the first medication fill
for PEG-IFN-alfa/ribavirin within this period was defined
as the index date. The 24-month study period included
12 months before and 12 months after the index date.
Treatment-naive HCV-infected patients were defined as
those who did not fill any prescriptions for PEG-IFN-alfa
prescription for at least 12 months before the first
such fill. HCV infection was defined by the presence
of at least 1 medical claim with an ICD-9-CM
(International Classification of Diseases, 9th Revision,
Clinical Modification) code for HCV (070.41x, 070.44,
070.51, 070.54, 070.7x) during the preindex period.
Patients were excluded if they were <18 years of
age or if they were not continuously enrolled during
the 24-month study period. We also excluded individuals
who initiated therapy at a dose not recommended by the
manufacturer [21-24]. Finally, we excluded patients
with certain medical claims during the preindex
period, including those with an ICD-9-CM code for
hepatitis B (070.2x, 070.3x),or hematologic malignancies for
which interferon may have been indicated [leukemia (204.
xx-208.xx), Hodgkin’s lymphoma (201.xx), non-Hodgkin’s
lymphoma (200, 202.0-202.2, 202.8), multiple myeloma
(203.0-203.1, 238.6), acute lymphocytic leukemia (204.0),
chronic lymphocytic leukemia (204.1), acute nonlympho-
cytic leukemia including acute myeloid leukemia
(205.0), acute monocytic leukemia (206.0), chronic
myeloid leukemia (205.1), or other leukemias (204.2,
204.8-204.9, 205.2, 205.8-205.9, 206.1-206.2, 206.8-206.9,
207.8, 208.0-208.2, 208.8-208.9)].
Outcome measures
The primary outcome variable was net incremental cost,
which was calculated as the difference between preindex
and postindex cost for a prespecified list of TECs (see
following paragraph) and their treatments, excluding the
cost of PEG-IFN-alfa/ribavirin therapy. Charges for TECs
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these events or pharmacy claims with National Drug
Codes for medications to treat the events. Charges for
visits lacking a code for one of the listed TECs were
not included. New TECs were defined by a medical
or pharmacy claim in the postindex period that was
not present in the preindex period.
TECs were grouped as blood disorders (anemia,
neutropenia, thrombocytopenia), gastrointestinal disorders
(nausea/vomiting, diarrhea), endocrine disorders (diabetes,
hyperthyroidism, hypothyroidism), psychiatric disorders
(depression, anxiety disorders, bipolar disorders, insomnia),
skin and subcutaneous disorders (alopecia, skin rash),
and other disorders (dyspnea, fatigue, headache).
Medications used to treat TECs were grouped similarly
and included those to treat blood disorders (epoetin alfa,
darbepoetin, filgastrim, and eltrombopag), endocrine
disorders (antidiabetes medications and thyroid agents),
psychiatric disorders (anxiolytics, antidepressants, antipsy-
chotics/antimanics, and hypnotics), skin disorders (topical
steroids), and other (antimigraine).
Secondary outcomes included the incidence of new
TECs, timing of such TECs, and the rate of discontinuation
of PEG-IFN-alfa/ribavirin therapy. PEG-IFN-alfa/ribavirin
therapy was considered to be discontinued if there were no
prescription fills for both medications for at least 60 days.
The date of discontinuation was defined as the last day the
patient had both PEG-IFN-alfa and ribavirin available,
based on the days of supply as reported in the pharmacy
claims. If PEG-IFN-alfa and ribavirin were discontinued on
different dates, the earlier date was used.
Covariates
Other measures included patient age, gender, race,
geographic region, and the presence of human immuno-
deficiency virus (HIV) infection/acquired immune defi-
ciency syndrome (AIDS). Because physician specialty
may impact cost and resource use, we identified the
specialty of each patient’s usual care physician using a
validated method. The specialty of the physician prescribing
therapy was not directly identifiable in the claims database.
Instead, the method counts all claims for evaluation
and management services and identifies the physician
specialty with the largest plurality of such claims [25].
Physician specialty was assigned using claims from
the preindex period.
Sensitivity analyses
The recommended PEG-IFN-alfa/ribavirin treatment
duration is either 24 or 48 weeks, depending on HCV
GT. Claims data are used to process payments and
generally do not contain clinical information such as
test results. However, GT data were available for a
small subset of study subjects and we thus exploreddiscontinuation rates for this subset in a sensitivity
analysis. In another sensitivity analysis, we restricted the
group of patients analyzed to those who were treated
beyond 28 weeks of PEG-IFN-alfa/ribavirin treatment,
under the assumption that they had GT-1 infection.
Statistical analysis
For descriptive analysis, percentages, medians, means,
and standard deviations were calculated for all baseline
variables. We reported the percentage of patients with
any new TEC as well as the percentage with a new event
for each TEC. We reported the mean and standard
deviations for TEC charges in both the pre- and postindex
periods and for net incremental TEC charges. Treatment
discontinuation was reported as the proportion of patients
who no longer had PEG-IFN-alfa/ribavirin available at
successive 4-week intervals. Charges for TECs were also
stratified by duration of therapy. All data transformations
and statistical analyses were performed using SAS version
9.2 (SAS Institute, Cary, NC).
Results
We identified 3,795 patients with HCV infection who
were newly treated with PEG-IFN-alfa/ribavirin during
the study period. Of these, 1,269 met the inclusion
criteria (Table 1), The most common reason for exclu-
sion (2,274 patients) was lack of continuous enrollment
for 24 months. One hundred thirty-eight patients were
excluded because of a co-occurring diagnosis of hepatitis
B or a hematologic malignancy, 16 because they lacked an
HCV diagnosis in the pre-index period, and 85 because
they had an initial dose of PEG-IFN-alfa/ribavirin other
than one of those recommended by the manufacturer.
Most of the included subjects were male (63.8%), with
85.1% between the ages of 40 and 59 years old (mean age,
50.2 years). Over half (55.6%) the patients were from
the South. Only 3.5% of patients in this sample were
coinfected with HIV. The most common treating
physician specialty was gastroenterology (32.4%), followed
by family practice (28.5%) and internal medicine (25.2%).
Table 2 shows the proportion of patients who had a
diagnosis recorded for each TEC before beginning
treatment (preindex period) and the proportion with
a diagnosis recorded for the TEC while they were
receiving treatment (postindex period). In addition,
the proportion of patients who had a new diagnosis
while receiving treatment (e.g., no such diagnosis in
the preindex period, followed by a diagnosis in the
postindex period) is shown. These newly diagnosed
conditions are considered to be TECs. Disorders of blood
were observed in 14.3% of patients in the preindex period
and in 41.2% of patients in the postindex period. In the
postindex period, 35.2% of patients had a new diagnosis
of a blood disorder and new psychiatric events were
Table 1 Characteristics of insured patients initiating
PEG-IFN-alfa and ribavirin treatment for chronic HCV
infection
Characteristic No. (%) of insured patients (n = 1269)


















AIDS, acquired immune deficiency syndrome; HCV, hepatitis C virus; HIV,
human immunodeficiency virus; PEG-IFN-alfa, pegylated interferon alpha.
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gastrointestinal events in 12.0%. Most (61.6%) patients
had at least 1 newly diagnosed TEC. The most common
TECs were anemia (29.2%), fatigue (16.4%), depression
(11.5%), neutropenia (11.0%), insomnia (8.98%), nausea/
vomiting (8.35%), skin rash (7.64%), hypothyroidism (6.93%),
thrombocytopenia (6.70%), dyspnea (5.99%), and headache
(5.91%).
The mean net incremental charge for the predefined
TEC in the postindex period was $6,377, comprising
$2,782 for medical and $3,595 for pharmacy claims. The
largest component of the incremental increase in
pharmacy costs was for medications to treat anemia
and neutropenia (mean increase, $3226; Figure 1). These
medications included epoetin alfa, darbepoetin, filgastrim,
and eltrombopag. The increase in non-drug-related charges
was greatest in patients who completed only 12 weeks
of PEG-IFN-alfa/ribavirin treatment (mean: $6,015;
range: −28,831 to 291,838) and least in patients who com-
pleted the 48-week treatment (mean: $291; range: −208,060
to 95,782).
Two hundred two patients (15.9%) discontinued
PEG-IFN-alfa/ribavirin treatment by 12 weeks. The
mean incremental TEC charge for this group was
$7,509 (range: −29,273 to 292,904). The mean incremental
charge was $8,202 (range: −57,384 to 226,864) in the 423patients who continued treatment for between 25 and
47 weeks and $6,249 (range: −207,548 to 130,297) in the
372 patients who completed 48 weeks of PEG-IFN-alfa/
ribavirin treatment (Figure 2).
Considering all study subjects, 14.2% discontinued
treatment before week 12, 32.8% before week 24, and
70.7% before week 48 (Table 3). In a sensitivity analysis
restricted to 238 patients for whom HCV GT was known,
81.1% (n = 193) had GT-1/4/6 and therefore these patients
should have received 48 weeks of PEG-IFN-alfa/ribavirin.
In this group of 193 patients, 14.5% discontinued
treatment before week 12, 31.6% before week 24, and
62.7% before week 48. In a second sensitivity analysis
restricted to patients treated beyond 28 weeks, and
therefore presumed to have predominately GT-1 infection,
39.8% discontinued PEG-IFN-alfa/ribavirin treatment
before week 48.
Discussion
In an insured US cohort with chronic HCV infection
who were treated with PEG-IFN-alfa/ribavirin, most
patients experienced one or more TEC. The most com-
monly identified TECs were anemia, fatigue, depression,
and neutropenia. Anemia was identified in 29.2% of
patients in this study, compared with in 22% of patients in
clinical trials. Rates of several adverse events including
fatigue (16%), insomnia (9%), and depression (12%) were
lower than those observed in clinical trials (54%, 37%,
22%, respectively) [10]. This may be expected since
patients in clinical practice are typically monitored
less aggressively than those in clinical trials. We used
ICD-9-CM codes to identify TECs, and thus we only
identified events that warranted an interaction with
the healthcare system in the form of an office visit,
hospitalization, or prescription. In addition, even when
identified clinically, ICD-9-CM codes may not be recorded
for less-severe events. As a result, the frequency and cost
of TECs we report may be underestimated.
Despite this likely downward bias, we estimated that
TECs increased direct treatment costs by 25% ($6,377),
with just over half of charges from prescription medications
and the rest from office visits, hospitalizations, and other
nonprescription charges. Although we did not assess
indirect costs in this study, several of the TECs (e.g.,
anemia, depression, and insomnia) experienced by patients
who receive PEG-IFN-alfa/ribavirin therapy have associated
indirect costs. For example, in studies of patients with
anemia due to chronic kidney disease, hemoglobin values
were positively correlated with days worked [26,27]. In a
study that reviewed healthcare claims from employees at a
major US corporation, nearly 20% of the costs of depressive
illness were related to disability, and this study did
not take into account lost productivity or sick leave
[28]. Depressed individuals took significantly more
Table 2 Frequency of various treatment-emergent comorbid eventsa in insured patients initiating PEG-IFN-alfa and
ribavirin treatment for chronic HCV infection
Variable No. (%) with treatment-emergent
comorbid event in the preindex period
No. (%) with treatment-emergent
comorbid event in the postindex period
No. (%) diagnosed with a new
treatment-emergent comorbid
event in the postindex periodb
(n = 1269) (n = 1269) (n = 1269)
Any treatment-related
comorbid event
803 (63.3) 923 (72.7) 782 (61.6)
Blood 182 (14.3) 523 (41.2) 446 (35.2)
Anemia 147 (11.6) 461 (36.3) 371 (29.2)
Neutropenia 18 (1.42) 144 (11.4) 139 (11.0)
Thrombocytopenia 46 (3.62) 101 (7.96) 85 (6.70)
Gastrointestinal 114 (8.98) 175 (13.8) 152 (12.0)
Nausea/vomiting 78 (6.15) 124 (9.77) 106 (8.35)
Diarrhea 55 (4.33) 75 (5.91) 63 (4.96)
Endocrine 317 (25.0) 354 (27.9) 154 (12.1)
Diabetes 214 (16.9) 217 (17.1) 61 (4.81)
Hyperthyroidism 20 (1.58) 30 (2.36) 26 (2.05)
Hypothyroidism 117 (9.22) 164 (12.9) 88 (6.93)
Psychiatric 262 (20.7) 375 (29.6) 255 (20.1)
Depression 181 (14.3) 266 (21.0) 146 (11.5)
Anxiety disorders 48 (3.78) 54 (4.26) 31 (2.44)
Bipolar disorders 22 (1.73) 27 (2.13) 17 (1.34)
Insomnia 82 (6.46) 143 (11.3) 114 (8.98)
Skin and subcutaneous 59 (4.65) 119 (9.38) 111 (8.75)
Alopecia 11 (0.87) 17 (1.34) 15 (1.18)
Skin rash 49 (3.86) 103 (8.12) 97 (7.64)
Other disorders 383 (30.2) 423 (33.3) 311 (24.5)
Dyspnea 91 (7.17) 98 (7.72) 76 (5.99)
Fatigue 270 (21.3) 319 (25.1) 208 (16.4)
Headache 96 (7.57) 100 (7.88) 75 (5.91)
HCV, hepatitis C virus; PEG-IFN-alfa, pegylated interferon alpha.
aICD-9-CM diagnosis code for listed events appearing in any diagnosis field.
bEvent appears during period when patient is being treated but not in pretreatment period.
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or back problems [28]. In addition, absenteeism and
disability expenditures were higher in individuals with
insomnia than those without it [29]. Together these
studies suggest that indirect costs of these TECs are
likely to be significant.
Shortened treatment duration was not associated with
a reduced cost of treating TECs. Nonprescription costs
accounted for most of the total costs in patients who
stopped treatment by 12 weeks and between 24 and
48 weeks, suggesting that these groups of patients
frequently experience TECs. The lowest cost of treating
TECs was for patients who stopped treatment between
13 and 24 weeks; most of these patients probably
discontinued treatment because they completed treatment
for GT 2/3 infection rather than because of TECs. Patientswho completed therapy at 48 weeks had the lowest
nonprescription costs but high prescription costs, possibly
indicating stable management of TECs such as anemia or
neutropenia with costly growth factors.
Although comparisons to other studies are difficult
because of differences in methodology, the mean treatment
duration of 215 days is consistent with estimates from other
studies of 172–240 days [15,16,19,30]. In a retrospective
cohort study of Veterans Affairs patients, two of the most
common TECs we identified, anemia and neutropenia,
were associated with lower persistence with PEG-IFN-alfa/
ribavirin treatment (mean 172 days) [30]. Similar to patients
in our study, the investigators identified patients with
anemia and neutropenia through both ICD-9-CM codes
and by identifying medication use (specifically the use of
growth factors). Growth factors may improve treatment
1-12 wk
n = 202 (15.9%)
13-24 wk
n = 272 (21.4%)
25-47 wk
n = 423 (33.3%)
48 wk
n = 372 (29.3%)
Mean (SD) [Median] Mean (SD) [Median] Mean (SD) [Median] Mean (SD) [Median]
Non-Rx 
charges 6,015 (28,057) [0] 1,122 (11,493) [0] 4,498 (22,796) [90] 291 (17,308) [40]
Rx 
chargesa 1,494 (6,069) [37] 1,752 (3,964) [168] 3,704 (7,091) [355] 5,958 (11,241) [544]
Total 
charges 7,509 (28,719) [182] 2,874 (12,326) [390] 8,202 (25,136) [940] 6,249 (20,335) [1,164]
aCompleted treatment
bCharges exclude HCV treatment-related costs
Figure 2 Increase in charges from 1-year preindex to 1-year postindex periods for treatment-related comorbid events, by treatment
duration. Data on four mutually exclusive groups are presented: those who discontinued PEG-IFN-alfa/ribavirin between weeks 1–12, weeks
13–24, weeks 25–47, and after week 47. For all groups, annual charges are shown.
Figure 1 Increase in non-medication-related and medication-related charges for treatment-emergent comorbid events between
preindex and postindex periods.
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Table 3 Duration and discontinuation of PEG-IFN-alfa/ribavirin therapy in insured patients receiving treatment for
chronic HCV infection








No. of patients Mean (SD) Median n (%) n (%) n (%)
All 1,269 214.8 (113.8) 195 180 (14.2) 416 (32.8) 897 (70.7)
Patients with known GT 238 223.1 (115.3) 211 32 (13.4) 79 (33.2) 165 (69.3)
GT 2/3 45 161.3 (60.4) 168 4 (8.9) 18 (40.0) 44 (97.8)
GT 1/4/6 193 237.5 (120.2) 282 28 (14.5) 61 (31.6) 121 (62.7)
Patients treated >28 weeksa 618 315.6 (57.1) 339 – – – – 246 (39.8)
GT, genotype; HCV, hepatitis C virus; PEG-IFN-alfa, pegylated interferon alpha.
aPresumed to have predominately GT-1 infection.
Sapra et al. BMC Health Services Research 2014, 14:429 Page 7 of 8
http://www.biomedcentral.com/1472-6963/14/429tolerability and thus enhance persistence. Dissimilarities in
data sources, clinical care settings, data analysis techniques,
and patient characteristics may explain some of the differ-
ences in the treatment discontinuation estimates. Although
we could not distinguish between patients who discontin-
ued therapy because of adverse events and those who
discontinued therapy because of lack of virologic response,
our findings support the concept that adverse events lead
to high rates of therapy discontinuation.
Limitations of this study include those common to
claims analysis. A commercially insured population may
not be representative of the entire US population nor of
treatment patterns in other countries. Lack of clinical
data can confound interpretation. In particular, HCV
treatment duration is dictated by GT, which was
unavailable for most patients in this study. HCV GT
was available for a subset of 238 patients. In this
subset, 81% had GT 1/4/6, which is similar to other
US cohorts, suggesting that our data are representa-
tive of the US population [31,32]. According to stand-
ard treatment recommendations, these patients with
predominately GT-1 would be expected to complete
48 weeks of treatment [33]. This subset of patients
had discontinuation rates that were similar to the
overall group, which suggests that our assumption
that treatment duration was indicative of GT was reason-
able. Furthermore, response guided therapy would lead
some patients to have treatment recommended beyond
48 weeks. If these patients continued treatment up to
48 weeks, they might be clinically discontinuing therapy
prematurely, whereas in our analysis they would not be
considered to have done so. Conversely, discontinuation
of therapy may be recommended when virologic response
is poor, and we could not distinguish between this
and TECs as a cause of discontinuation. This study
was intended to examine only one aspect of cost, not
total treatment costs or cost effectiveness. HCV treatment
with PEG-IFN-alfa/ribavirin costs between $23,000 and
$78,000 per year, and newer treatments are substantially
more expensive [17]. Given the timing of this study,none of the patients were treated with newer direct
acting antivirals.
In an additional sensitivity analysis of the patients who
stopped therapy after 28 weeks and were thus presumed
to have GT 1/4/6, 40% stopped before completing the
recommended duration of therapy. Patients treated
over 12 weeks with GT-1 would be expected to have
had a virologic response [33] and thus discontinuations
after 24 weeks would most likely be due to adverse events
in those with GT-1. Overall, these sensitivity analyses
further support the idea that discontinuation rates in
patients treated with PEG-IFN-alfa/ribavirin are high
and frequently due to TECs.
Additional limitations include miscoding or undercoding
of claims, which may affect the accuracy of cost estimates.
Finally, although we were only able to study patients
who were receiving double therapy, the cost of TECs
may rise with the use of triple therapy (PEG-IFN-alfa/
ribavirin plus a protease inhibitor) because gastrointestinal
events, skin rash, and anemia are more common with
triple therapy than with PEG-IFN-alfa/ribavirin alone
[10,14,34].
Conclusion
Treatment of chronic HCV infection with PEG-IFN-alfa/
ribavirin led to frequent TECs and that these events were
associated with significant costs. Furthermore, nearly
half of treated patients discontinued therapy. It is
likely that adding a protease inhibitor to the PEG-IFN-
alfa/ribavirin treatment discussed in this study will result
in similar or increased TECs. Thus, better-tolerated
therapies associated with fewer TECs that reduce health-
care system costs and improve patient continuation rates
are needed.
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